![](/img/cover-not-exists.png)
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Ascierto, Paolo Antonio, Del Vecchio, Michelle, Mackiewicz, Andrzej, Robert, Caroline, Chiarion-Sileni, Vanna, Arance, Ana, Lebbé, Céleste, Svane, Inge Marie, McNeil, Catriona, Rutkowski, Piotr, LoqVolume:
8
Journal:
Journal for ImmunoTherapy of Cancer
DOI:
10.1136/jitc-2019-000391
Date:
June, 2020
File:
PDF, 1.92 MB
2020